Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asad Bashey

Showing results (71-80 of 128) with videos related to

Pageof 13
Sort By:
Transplantation and Cellular Therapy|March 29, 2021
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical TrialBart L Scott, Marcelo C Pasquini, Mingwei Fei, et al.
Blood Advances|May 13, 2020
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantationMonzr M Al Malki, Dongyun Yang, Myriam Labopin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant CyclophosphamideAsad Bashey, Mei-Jie Zhang, Shannon R McCurdy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialEdward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic TransplantationStephanie J Lee, Brent Logan, Mary M Horowitz, et al.
JCO Precision Oncology|May 26, 2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic SyndromeLaura W Dillon, Gege Gui, Brent R Logan, et al.
Haematologica|July 6, 2023
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaborationTania Jain, Hua-Ling Tsai, Hany Elmariah, et al.
Blood Advances|May 26, 2018
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?Tara M Robinson, Ephraim J Fuchs, Mei-Jie Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2008
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplantSonali M Smith, Koen van Besien, Jeanette Carreras, et al.
Blood|May 5, 2017
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHDBradley M Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Pageof 13

Showing results (71-80 of 128) with videos related to

Sort By:
Pageof 13
Transplantation and Cellular Therapy|March 29, 2021
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical TrialBart L Scott, Marcelo C Pasquini, Mingwei Fei, et al.
Blood Advances|May 13, 2020
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantationMonzr M Al Malki, Dongyun Yang, Myriam Labopin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant CyclophosphamideAsad Bashey, Mei-Jie Zhang, Shannon R McCurdy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialEdward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic TransplantationStephanie J Lee, Brent Logan, Mary M Horowitz, et al.
JCO Precision Oncology|May 26, 2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic SyndromeLaura W Dillon, Gege Gui, Brent R Logan, et al.
Haematologica|July 6, 2023
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaborationTania Jain, Hua-Ling Tsai, Hany Elmariah, et al.
Blood Advances|May 26, 2018
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?Tara M Robinson, Ephraim J Fuchs, Mei-Jie Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2008
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplantSonali M Smith, Koen van Besien, Jeanette Carreras, et al.
Blood|May 5, 2017
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHDBradley M Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Pageof 13